Mesoblast Ltd (ASX: MSB) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Mesoblast Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Mesoblast Ltd (ASX: MSB)
Latest News
How to invest
Building a $1 million portfolio with ASX shares and the magic of compound interest
Healthcare Shares
Mesoblast share price surges 11% following horror start to August
Healthcare Shares
This $9 billion investor is selling off Mesoblast shares. Should you?
Healthcare Shares
Mesoblast shares continue slide, but this ASX biotech stock is soaring 23%!
Share Fallers
Why Lake Resources, Mesoblast, New Hope, and ResMed shares are falling today
Healthcare Shares
What this broker is saying about Mesoblast shares following the selloff
Share Fallers
Why Block, Flight Centre, Mesoblast, and ResMed shares are dropping
Healthcare Shares
Mesoblast share price crashes 58% after FDA blow
Healthcare Shares
Is no FDA news bad news for Mesoblast shares?
Healthcare Shares
Mesoblast share price frozen ahead of FDA news
Share Fallers
Why Credit Corp, Mesoblast, Talon Energy, and Weebit Nano shares are falling
Share Fallers
Why 29Metals, Core Lithium, Domino’s, and Mesoblast shares are falling
MSB ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About Mesoblast Ltd
Mesoblast Ltd is a clinical-stage biotechnology company. It develops and commercializes innovative allogeneic cellular medicines to treat complex diseases resistant to the conventional standard of care. Its portfolio of Phase 3 product candidates comprises remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), and for moderate to severe acute respiratory distress syndrome (ARDS) and others.
MSB Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
09 Aug 2023 | $0.35 | $-0.03 | -8.00% | 37,247,579 | $0.39 | $0.39 | $0.35 |
08 Aug 2023 | $0.38 | $-0.04 | -9.76% | 18,336,059 | $0.42 | $0.43 | $0.38 |
07 Aug 2023 | $0.41 | $-0.06 | -12.77% | 36,073,958 | $0.47 | $0.48 | $0.40 |
04 Aug 2023 | $0.47 | $-0.62 | -56.88% | 68,696,512 | $0.50 | $0.55 | $0.46 |
01 Aug 2023 | $1.09 | $-0.05 | -4.37% | 5,995,187 | $1.15 | $1.15 | $1.08 |
31 Jul 2023 | $1.15 | $0.00 | 0.00% | 3,809,699 | $1.18 | $1.21 | $1.14 |
28 Jul 2023 | $1.15 | $-0.02 | -1.72% | 2,924,575 | $1.18 | $1.19 | $1.15 |
27 Jul 2023 | $1.17 | $-0.02 | -1.69% | 3,386,451 | $1.21 | $1.21 | $1.16 |
26 Jul 2023 | $1.19 | $-0.02 | -1.66% | 3,070,595 | $1.18 | $1.20 | $1.13 |
25 Jul 2023 | $1.21 | $-0.07 | -5.49% | 3,926,158 | $1.26 | $1.26 | $1.18 |
24 Jul 2023 | $1.28 | $-0.09 | -6.59% | 3,840,730 | $1.39 | $1.39 | $1.26 |
21 Jul 2023 | $1.37 | $-0.02 | -1.44% | 1,330,015 | $1.38 | $1.39 | $1.37 |
20 Jul 2023 | $1.39 | $0.00 | 0.00% | 2,295,423 | $1.40 | $1.40 | $1.37 |
19 Jul 2023 | $1.39 | $0.01 | 0.73% | 2,291,003 | $1.40 | $1.41 | $1.38 |
18 Jul 2023 | $1.37 | $-0.02 | -1.44% | 4,116,753 | $1.41 | $1.42 | $1.36 |
17 Jul 2023 | $1.39 | $0.00 | 0.00% | 3,601,843 | $1.40 | $1.43 | $1.37 |
14 Jul 2023 | $1.39 | $0.11 | 8.56% | 6,025,849 | $1.32 | $1.40 | $1.31 |
13 Jul 2023 | $1.29 | $0.04 | 3.21% | 2,646,842 | $1.26 | $1.31 | $1.26 |
12 Jul 2023 | $1.25 | $0.04 | 3.32% | 1,428,359 | $1.22 | $1.25 | $1.21 |
11 Jul 2023 | $1.21 | $0.08 | 7.08% | 2,204,535 | $1.15 | $1.21 | $1.14 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
07 Jul 2023 | Silviu Itescu | Issued | 2 | $2,627,250 |
Issue of options.
|
07 Jul 2023 | Eric Rose | Issued | 2 | $2,429,500 |
Issue of options.
|
05 Jun 2023 | Philip Krause | Buy | 20 | $74,100 |
On-market trade. US$, 100,000 ordinary shares held in the form of 20,000 ADSs
|
16 Jan 2023 | Jane Bell | Issued | 200 | $195,000 |
Issue of options.
|
16 Jan 2023 | Philip Krause | Issued | 200 | $195,000 |
Issue of options.
|
25 Nov 2022 | Silviu Itescu | Issued | 1 | $1,565,500 |
Issue of options.
|
13 Sep 2022 | William (Bill) Burns | Buy | 22 | $20,020 |
On-market trade.
|
07 Sep 2022 | Jane Bell | Buy | 133 | $109,999 |
On-market trade.
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Mr Michael Robert Spooner | Non-Executive Director | Sep 2004 |
Mr Spooner has served on the Board of Directors since 2004. During this period he has filled various roles including as Chairman from the date of the ASX public listing in 2004 until 2007. Over the past several years Mr Spooner has served on the board of directors in various capacities at several Australian and international biotechnology companies, including BiVacor Pty Ltd (2009- 2013), Advanced Surgical Design & Manufacture Limited (2010-2011), Peplin, Inc. (2004-2009), Hawaii Biotech, Inc. (2010-2012), Hunter Immunology Limited (2007-2008), and Ventracor Limited (2001-2003). He has been the Chairman of Simavita Ltd since May 2016 and Chairman of MicrofluidX since February 2018. Prior to returning to Australia in 2001, Mr Spooner spent much of his career internationally where he served in various roles including as a partner to PA Consulting Group, a UK-based management consultancy, and a Principal Partner and Director of Consulting Services with PricewaterhouseCoopers (Coopers & Lybrand) in Hong Kong. In addition Mr Spooner has owned and operated several international companies providing services and has consulted to a number of U.S. and Asian public companies. Mr Spooner provides executive management, commercial, business strategy and accounting expertise as well as established relationships with investment firms and business communities worldwide
|
Professor Silviu Itescu | Chief Executive OfficerExecutive Director | Jun 2004 |
Dr Itescu is our Chief Executive Officer (CEO). He has served our board of directors since our founding in 2004, was Executive Director from 2007 to 2011, and became CEO and Managing Director in 2011. Prior to founding Mesoblast in 2004, Dr Itescu established an international reputation as a physician scientist in the fields of stem cell biology, autoimmune diseases, organ transplantation, and heart failure. He has been a faculty member of Columbia University in New York, and of Melbourne and Monash universities in Australia. In 2011, Dr Itescu was named BioSpectrum Asia Person of the Year. In 2013, he received the inaugural Key Innovator Award from the Vatican's Pontifical Council for Culture for his leadership in translational science and clinical medicine in relation to adult stem cell therapy. Dr Itescu has consulted for various international pharmaceutical companies, has been an adviser to biotechnology and health care investor groups, and has served on the board of directors of several publicly listed life sciences companies
|
Dr Eric A Rose | Non-Executive Director | Apr 2013 |
Dr Rose has served on our board of directors since 2013. From 2007 through 2021, Dr Rose was with SIGA Technologies initially as CEO from 2007 to 2017 and then Chairman. From 2008 through 2012, Dr Rose served as the Edmond A. Guggenheim Professor and Chairman of the Department of Health Evidence and Policy at the Mount Sinai School of Medicine. From 1994 through 2007, Dr Rose served as Chairman of the Department of Surgery and Surgeon-in-Chief of the Columbia Presbyterian Center of New York Presbyterian Hospital. From 1982 through 1992, he led the Columbia Presbyterian heart transplantation program in the United States. Dr Rose currently sits on the board of directors of ABIOMED. His experience as a surgeon, researcher and businessman provides medical, pharmaceutical, scientific and industry expertise.
|
Mr William (Bill) A Burns | Non-Executive DirectorVice-Chairman | Mar 2014 |
Mr Burns has served on our board of directors since 2014 and was appointed Vice Chairman in 2016. He spent his entire management career at the Beecham Group and F. Hoffmann-La Roche Ltd. He was Chief Executive Officer of Roche Pharmaceuticals from 2001 to 2009, when he joined the board of directors of F. Hoffmann-La Roche Ltd. until he retired in 2014. He is the Chair of Molecular Partners, and has been a Non-Executive Director of Shire PLC, Chugai Pharmaceutical Co., Genentech, Crucell, and Chairman of Biotie Therapies Corp. from 2014 until its sale to Acorda Therapeutics Inc. in 2016. Mr Burns is also a member of the Oncology Advisory Board of the Universities of Cologne/Bonn in Germany. In 2014, he was appointed a trustee of the Institute of Cancer Research, London, and from March 2016 until April 2020 a Governor of The Wellcome Trust in London, UK. His extensive experience in the pharmaceutical industry, specifically as a member of the board of directors of other pharmaceutical companies, provides pharmaceutical, healthcare, industry, leadership and management expertise.
|
Ms Jane Catherine Bell | Non-Executive Director | Aug 2022 |
Ms Bell has 22 years of corporate finance experience focussing on international investment transactions in the United States, Canada, Australia and the United Kingdom, including funds management, mergers, acquisitions, and divestments. She has served as a non-executive Director in a diverse range of highly regulated sectors including delivery of healthcare, life sciences, medical research, and funds management. Ms Bell currently serves as Deputy Chair of Monash Health. From 2014 until 2021 she was a director of U Ethical, Australia's first ethical funds manager, and a member of its Investment Committee. She has also been a director of Hudson Institute of Medical Research, is currently a director of Amplia Therapeutics, and Chairs Advisory Groups for the Royal Australian and New Zealand College of Obstetricians and Melbourne Genomics Health Alliance.
|
Mr Joseph R Swedish | Non-Executive DirectorNon-Executive Chairman | Jun 2018 |
Mr Swedish has more than two decades of healthcare leadership experience as the CEO for major United States healthcare enterprises. Most recently, he has served as Executive Chairman, President and CEO of Anthem Inc., America's leading health benefits provider. Prior to joining Anthem, Mr Swedish was CEO for several major integrated healthcare delivery systems, including Trinity Health and Colorado's Centura Health. Currently, he sits on the board of directors of IBM Corporation, CDW Corporation, and Centrexion Therapeutics. Mr Swedish is a member and previously Chairman of Duke University's Fuqua School of Business Board of Visitors. Previously, he was Chairman of the Catholic Health Association and the America's Health Insurance Plans.
|
Mr Philip J. Facchina | Non-Executive Director | Mar 2021 |
Mr Facchina brings more than 35 years of experience in corporate strategy, capital markets, finance, and business development across several industries, including healthcare. Since 2018, Mr. Facchina has been Chief Strategy Officer at SurgCenter Development, the largest privately held operator of ambulatory surgery centers in the US, overseeing the company's strategic relationships, including its relationships with the broad US ASC market, certain hospital systems and other market constituents. Prior to SurgCenter, Mr Facchina spent two decades in the public and private capital markets, where he managed liquid and illiquid portfolios, and managed public and private capital transactions of equity and debt, led M&A and special advisory processes including take-privates. From 2008 to 2017, Mr. Facchina served as a Partner, Co-Portfolio Manager and the Chief Operating Officer of Ramsey Asset Management, an institutional investment management firm, and from 1998 to 2008 Mr. Facchina led the technology, media and communications and healthcare investment banking groups of FBR Capital Markets. Mr Facchina currently serves as an independent director for ViON 84 Corporation and Millennium Global Treasury Services, and is Advisor to the CEO of Johanna Foods Inc, where he heads the Audit Committee and he also serves as an advisor to New Markets Venture Partners. Previously, among other directorships and committee posts, Mr Facchina served on the Board of Web.com, where he led Corporate Governance. Mr Facchina is a qualified financial expert for SEC and NASDAQ purposes
|
Dr Philip R Krause | Non-Executive Director | Mar 2022 |
Dr Krause was for the past decade Deputy Director, Office of Vaccines Research and Review (OVRR) at the US Food and Drug Administration (FDA)'s Center for Biologics Evaluation and Research (CBER). Dr Krause is currently Chair of the World Health Organization COVID Vaccines Research Expert Group, and most recently he shared responsibility for regulatory authorizations of COVID-19 vaccines in the US. His experience includes regulation and development of biological products, including interdisciplinary team-based review process for clinical (safety and efficacy) and CMC (product quality) issues throughout the product life cycle, through Phase 3 clinical development and post-marketing phases. In a 30-year career at FDA Dr Krause has collaborated with international and US domestic stakeholders including the European Medicines Association (EMA), Biomedical Advanced Research and Development Authority (BARDA), and the National Institutes of Health (NIH).
|
Mr Charlie Harrison | Company Secretary | Sep 2014 |
-
|
Ms Niva Sivakumar | Joint Company Secretary | Oct 2019 |
-
|
Mr Paul Hughes | Joint Company Secretary | Apr 2022 |
-
|
Charlie Harrison | Company Secretary |
-
|
|
Paul Hughes | Joint Company Secretary |
-
|
|
Niva Sivakumar | Joint Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
J P Morgan Nominees Australia Pty Limited | 149,080,438 | 20.28% |
HSBC Custody Nominees (Australia) Limited | 138,678,706 | 18.86% |
Professor Silviu Itescu | 67,751,838 | 9.22% |
Citicorp Nominees Pty Limited | 43,160,015 | 5.87% |
BNP Paribas Noms Pty Ltd | 14,826,231 | 2.02% |
UBS Nominees Pty Ltd | 14,169,957 | 1.93% |
Thorney Holdings Pty Ltd | 10,000,000 | 1.36% |
Tiga Trading Pty Ltd | 10,000,000 | 1.36% |
Independent Asset Management Pty Limited | 7,760,558 | 1.06% |
HSBC Custody Nominees (Australia) Limited A/C 2 | 6,396,611 | 0.87% |
MERRILL LYNCH (AUSTRALIA) NOMINEES PTY LIMITED | 5,750,843 | 0.78% |
National Nominees Limited | 4,532,645 | 0.62% |
Mr Gregory John Matthews & Mrs Janine Marie Matthews | 3,886,063 | 0.53% |
Tigcorp Nominees Pty Ltd | 1,995,000 | 0.27% |
BNP Paribas Noms Pty Ltd i | 1,810,573 | 0.25% |
Lalp Pty Ltd | 1,647,144 | 0.22% |
BNP PARIBAS NOMINEES PTY LTD | 1,414,665 | 0.19% |
Beth Sackstein | 1,277,210 | 0.17% |
Dr Siong Wei Hong | 1,260,151 | 0.17% |
Mr Fei Tian | 1,200,000 | 0.16% |
Mr Muthiah John Hilbert | 1,190,801 | 0.16% |